Paraoxonase 1 and platelet-activating factor acetylhydrolase activities in patients with low HDL-cholesterol levels with or without primary hypertriglyceridemia

被引:36
作者
Brites, FD
Verona, J
Schreier, LE
Fruchart, JC
Castro, GR
Wikinski, RL
机构
[1] Univ Buenos Aires, Fac Farm & Bioquim, Lab Lipidos & Lipoprot, Dept Bioquim Clin, RA-1113 Buenos Aires, DF, Argentina
[2] Inst Pasteur, INSERM, Unite 545, Serv Etud & Rech Lipoprot & Atherosclerose, F-59019 Lille, France
关键词
paraoxonase; 1; platelet-activating factor acetylhydrolase; HDL; hypoalphalipoproteinemia; hypertriglyceridemia;
D O I
10.1016/j.arcmed.2004.02.002
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background. Previous studies have shown that high density lipoprotein (HDL)-deficient states are associated with reduced paraoxonase I (PON 1) activity. However, HDL reduction caused by primary hypertriglyceridemia has not been fully explored. The aim of the present study was to evaluate whether PON1 and platelet-activating factor acetylhydrolase (PAF-AH), two anti oxidant enzymes, were altered in patients with low HDL-cholesterol levels with or without primary hypertriglyceridemia in comparison with control normolipemic subjects. Methods. We studied 24 patients with low HDL-cholesterol levels with (n = 12) or without (n = 12) primary hypertriglyceridemia in comparison with 12 control subjects who presented normal HDL-cholesterol and trialyceride levels. Paraoxon and phenylacetate C, were used as substrate for measuring PON] activities and 1-hexadecyl-2-[3(H)]acetyl-glycero-3-phosphocholine for platelet-activating factor acetylhydrolase (PAF-AH) activity. Double substrate method was used to assign phenotypes. Lipid, lipoprotein, apolipoprotein, and lipoprotein particles were determined by standardized methods. Results. Both PON1 activities were significantly reduced in patients with low HDL-cholesterol levels. This reduction could be selectively attributed to the hypertriglyceridemic subgroup. PAF-AH activity was not different between hypoalphalipoproteinemic patients and controls. PON] activities correlated positively and significantly with HDL-cholesterol, HDL2-cholesterol, HDL3-cholesterol, HDL-phospholipids, apo A-I, apo A-II, and LpA-I:A-II. PAF-AH correlated positively and significantly with total and low density lipoprotein-cholesterol. Conclusions. Data from this study would suggest that in hypoalphalipoproteinemic syndrome, particularly when associated with hypertriglyceridemia, there is impairment in enzymatic antioxidant activity exclusively related with HDL. (C) 2004 IMSS. Published by Elsevier Inc.
引用
收藏
页码:235 / 240
页数:6
相关论文
共 31 条
[1]   ATHEROGENIC LIPOPROTEIN PHENOTYPE - A PROPOSED GENETIC-MARKER FOR CORONARY HEART-DISEASE RISK [J].
AUSTIN, MA ;
KING, MC ;
VRANIZAN, KM ;
KRAUSS, RM .
CIRCULATION, 1990, 82 (02) :495-506
[2]   Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions - A possible peroxidative role for paraoxonase [J].
Aviram, M ;
Rosenblat, M ;
Bisgaier, CL ;
Newton, RS ;
Primo-Parmo, SL ;
La Du, BN .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (08) :1581-1590
[3]   INACTIVATION OF 1-ALKYL-2-ACETYL-SN-GLYCERO-3-PHOSPHOCHOLINE BY A PLASMA ACETYLHYDROLASE - HIGHER ACTIVITIES IN HYPERTENSIVE RATS [J].
BLANK, ML ;
HALL, MN ;
CRESS, EA ;
SNYDER, F .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1983, 113 (02) :666-671
[4]   IDENTIFICATION OF A DISTINCT HUMAN HIGH-DENSITY-LIPOPROTEIN SUBSPECIES DEFINED BY A LIPOPROTEIN-ASSOCIATED PROTEIN, K-45 - IDENTITY OF K-45 WITH PARAOXONASE [J].
BLATTER, MC ;
JAMES, RW ;
MESSMER, S ;
BARJA, F ;
POMETTA, D .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1993, 211 (03) :871-879
[5]  
BRITES FD, 1999, ATHEROSCLEROSIS, V152, P179
[6]   Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase:: a potential new risk factor for coronary artery disease [J].
Caslake, MJ ;
Packard, CJ ;
Suckling, KE ;
Holmes, SD ;
Chamberlain, P ;
Macphee, CH .
ATHEROSCLEROSIS, 2000, 150 (02) :413-419
[7]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[8]   Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population [J].
Ferré, N ;
Camps, J ;
Fernández-Ballart, J ;
Arija, V ;
Murphy, MM ;
Ceruelo, S ;
Biarnés, E ;
Vilelle, E ;
Tous, M ;
Joven, J .
CLINICAL CHEMISTRY, 2003, 49 (09) :1491-1497
[9]   SPECTROPHOTOMETRIC ASSAYS FOR THE ENZYMATIC-HYDROLYSIS OF THE ACTIVE METABOLITES OF CHLORPYRIFOS AND PARATHION BY PLASMA PARAOXONASE ARYLESTERASE [J].
FURLONG, CE ;
RICHTER, RJ ;
SEIDEL, SL ;
COSTA, LG ;
MOTULSKY, AG .
ANALYTICAL BIOCHEMISTRY, 1989, 180 (02) :242-247
[10]   Evidence for a paraoxonase-independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein [J].
Graham, A ;
Hassall, DG ;
Rafique, S ;
Owen, JS .
ATHEROSCLEROSIS, 1997, 135 (02) :193-204